Methods and compositions for producing antigenic responses
View Patent ↗The present invention relates to methods of producing an antigenic response in which an antigen is contacted to an antigen-presenting cell, wherein the improvement comprises contacting the antigen-presenting cell with an A 1 adenosine receptor activating agent in an amount sufficient to increase the antigenic response of the antigen-presenting cell to the antigen. The present invention further provides methods, compositions, combination therapies, imaging techniques, and diagnostic kits that may improve the diagnosis, prognosis, and/or survival of cancer patients, pathogen-infected patients, and infectious or non-infectious immune-deficient patients.
1. A method of producing an antigenic response in a dendritic cell for injection into a patient, comprising first transfecting, lipofecting, or electroporating CD34+ progenitor cells ex vivo with a nucleotide sequence that encodes an A 1 adenosine receptor, then transfecting, lipofecting or electroporating the CD 34+ progenitor cells ex vivo with a mRNA encoding one or more tumor antigens, and lastly differentiating the CD 34+ progenitor cells ex vivo into dendritic cells which are capable of producing an antigenic response of the dendritic cell to the tumor antigen after injection into the patient.
2. The method of claim 1 , wherein said dendritic cell is administered to a subject and the antigenic response is an adaptive immune response or an innate immune response.
3. The method of claim 1 , wherein the dendritic cell expresses at least one A 1 adenosine receptor.
4. The method of claim 1 , wherein said transfecting, lipofecting or electroporating step is carried out in vitro.
5. The method of claim 1 , wherein the nucleotide sequence is a cDNA encoding a human A 1 adenosine receptor.
6. The method of claim 1 further comprising contacting the dendritic cell with an A 1 adenosine receptor agonist.
7. The method of claim 1 , wherein the antigenic response is an adaptive immune response or an innate immune response.
8. The method of claim 1 , wherein said antigenic response is an immune response.
9. The method of claim 8 wherein the immune response is an increase in responsiveness to the tumor antigen.
10. The method of claim 8 , wherein the dendritic cell is administered to a subject and the immune response is the production of higher antibody titres, increase in antibody affinity or generation of cytotoxic cells.
11. The method of claim 8 , wherein the immune response is the generation of cytotoxic cells.
12. The method of claim 1 , further comprising the step of: priming the antigen-presenting cell by contacting the antigen-presenting cell with a priming agent in an amount sufficient to prime the antigen-presenting cell, wherein the priming agent is phorbol myristoyl acetate (PMA).
13. The method of claim 12 further comprising contacting the dendritic cell with an A 1 adenosine receptor agonist.
14. A method of enhancing A 1 adenosine receptor signaling in a dendritic cell, comprising first transfecting, lipofecting or electroporating CD34+ progenitor cells ex vivo with a nucleotide sequence that encodes an A 1 adenosine receptor, then transfecting, lipofecting or electroporating the CD 34+ progenitor cells ex vivo with a mRNA encoding one or more tumor antigens, and lastly differentiating the CD 34+ progenitor cells ex vivo into dendritic cells which are capable of enhancing A 1 adenosine receptor signaling in the dendritic cell.
15. The method of claim 14 , wherein enhancing A 1 adenosine receptor signaling comprises correcting an A 1 adenosine receptor deficiency in the dendritic cell.
16. The method of claim 14 , wherein the nucleotide sequence is a cDNA encoding a human A 1 adenosine receptor.